Document is current
Any future updates will be listed below
-
Authors
Temedda, Mohamed Nour https://orcid.org/0009-0003-1495-5799
Garnier-Crussard, Antoine
Moutet, Claire
Mouchoux, Christelle
Dauphinot, Virginie
-
Funding
Funding for this research was provided by:
Hospices Civils de Lyon
- License Information
-
More Information
Article History
Received: 20 May 2025
Revised: 14 July 2025
Accepted: 4 August 2025
First Online: 27 August 2025
Declarations
:
: Independent of this work, A.G.C is an unpaid sub-investigator or local principal investigator in NCT04867616 (UCB Pharma), NCT04241068 (Biogen), NCT05310071 (Biogen), NCT03446001 (TauRx Therapeutics), NCT03444870 (Roche), NCT04374253 (Roche), NCT04777396 (Novo Nordisk), NCT04777409 (Novo Nordisk), NCT04770220 (Alzheon), NCT05423522 (Medesis Pharma), NCT06079190 (GlaxoSmithKline), NCT06159673 (Acadia), NCT05531526 (Aribio). M.N.T, C.Mt, C.Mc and VD declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This manuscript has not been published or submitted elsewhere. All authors have contributed significantly, and all authors are in agreement with the content of the manuscript.
: The MEMORA cohort protocol (clinicaltrial.gov number NCT02302482) has been approved by the regional ethics committee (Comité de protection des personnes Sud Est III) on July 29, 2014. Data processing has been approved by the national data protection commission.
: Not applicable.
